Ultragenyx Pharmaceutical Inc.
RAREUltragenyx Pharmaceutical Inc. (RARE) is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Established to address the unmet medical needs of patients with serious, life-threatening conditions, the company specializes in innovative treatments targeting underlying genetic causes.
Company News
The Portnoy Law Firm has initiated an investigation into possible securities fraud at Ultragenyx Pharmaceutical following the company's announcement that its Phase III Orbit and Cosmic studies failed to achieve primary endpoints for setrusumab in treating Osteogenesis Imperfecta. Despite improvements in secondary endpoints for bone material densi...
Ultragenyx Pharmaceuticals stock plummeted 42.35% after the company announced disappointing Phase 3 results for setrusumab, a potential treatment for osteogenesis imperfecta. Two studies (Orbit and Cosmic) failed to meet their primary endpoints, contrasting with earlier promising Phase 2 data. Multiple analysts have reduced their price targets on...
The article discusses the Vanguard Russell 1000 Growth ETF as an attractive investment option, highlighting its low-cost, diversified approach to tracking large-cap U.S. stocks with strong growth potential.
Ultragenyx Pharmaceutical granted 113,572 restricted stock units to 33 newly hired non-executive officers, with units vesting over four years and subject to continuous employment.
Pomerantz Law Firm is investigating potential securities fraud by Mereo BioPharma Group and Ultragenyx Pharmaceutical following a significant stock price drop after announcing a delayed final analysis of a Phase 3 clinical study.
